瘤内微生物代谢对肿瘤的双重效应

Dual Effects of Intratumoral Microbial Metabolism on Tumors

摘要

研究已证实，肿瘤组织内部并不是无菌状态，而是定植着具有肿瘤特异性的微生物群落。这些瘤内微生物不仅自身能直接促进或抑制肿瘤，还可以通过活跃的代谢活动，影响肿瘤的发生发展及治疗响应。分别从促肿瘤与抗肿瘤两个角度，综述瘤内微生物代谢对肿瘤的作用及其机制，总结基于瘤内微生物代谢的肿瘤防治新策略。瘤内微生物代谢对肿瘤的精准调控网络仍需深入研究，解析其对肿瘤的双重效应及分子机制，有望为肿瘤防治提供新方向。

Abstract

Research has confirmed that tumor tissues are not in a sterile state, but rather host microbial communities with tumor-specific characteristics. These intratumoral microorganisms not only directly promote or inhibit tumorigenesis themselves, but can also influence tumor development and therapeutic responses through their active metabolic activities. This review examines the effects and mechanisms of intratumoral microbial metabolism on tumors from both pro-tumoral and anti-tumoral perspectives, and summarizes novel strategies for tumor prevention and treatment based on intratumoral microbial metabolism. The precise regulatory network of intratumoral microbial metabolism on tumors requires further investigation. Elucidating its dual effects and molecular mechanisms on tumors is expected to provide new directions for tumor prevention and treatment.

关键词

瘤内微生物 / 代谢 / 肿瘤 / 治疗

Key words

Intratumoral microbiota / Metabolism / Tumor / Therapy

参考文献

[1] 金心怡, 钟悦欣, 张永芳, 等. 2021年中国恶性肿瘤疾病负担现状及趋势研究[J]. 卫生软科学, 2025, 39(11): 21-25.

[2] 夏斌斌, 黄融雪, 杨红菊, 等. 中国地域性及民族特异性肠道微生物组特征及其对疾病的影响[J]. 昆明医科大学学报, 2025, 46(11): 1-10.

[3] Gao Y Q, Tan Y J, Fang J Y. Roles of the gut microbiota in immune-related adverse events: Mechanisms and therapeutic intervention[J]. Nat Rev Clin Oncol, 2025, 22(7): 499-516.

[4] Nobels A, van Marcke C, Jordan B F, et al. The gut microbiome and cancer: From tumorigenesis to therapy[J]. Nat Metab, 2025, 7(5): 895-917.

[5] Narunsky-Haziza L, Sepich-Poore G D, Livyatan I, et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions[J]. Cell, 2022, 185(20): 3789-3806.e17.

[6] Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494): 973-980.

[7] Huang J T, Mao Y Q. The impact of the microbiome in cancer: Targeting metabolism of cancer cells and host[J]. Front Oncol, 2022, 12: 1029033.

[8] de Visser K E, Joyce J A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403.

[9] Jin M Z, Jin W L. The updated landscape of tumor microenvironment and drug repurposing[J]. Signal Transduct Target Ther, 2020, 5: 166.

[10] Chen Z, Han F, Du Y, et al. Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions[J]. Signal Transduct Target Ther, 2023, 8(1): 70.

[11] Galeano Niño J L, Wu H, LaCourse K D, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer[J]. Nature, 2022, 611(7937): 810-817.

[12] Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy[J]. Science, 359(6382): 1366-1372.

[13] Forbes N S. Engineering the perfect (bacterial) cancer therapy[J]. Nat Rev Cancer, 2010, 10(11): 785-794.

[14] Li X, Yang Y, Zhang B, et al. Lactate metabolism in human health and disease[J]. Signal Transduct Target Ther, 2022, 7: 305.

[15] Hezaveh K, Shinde R S, Klötgen A, et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress antitumor immunity[J]. Immunity, 2022, 55(2): 324-340.e8.

[16] Pascual G, Avgustinova A, Mejetta S, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36[J]. Nature, 2017, 541(7635): 41-45.

[17] Yang S, Hu Y, Cui M, et al. Microbiome, metabolome, and ionome profiling of cyst fluids reveals heterogeneity in pancreatic cystic neoplasms[J]. Cancer Lett, 2025, 623: 217730.

[18] Sha G, Wu Z, Wang B, et al. Intratumorally specific microbial-derived lipopolysaccharide contributes to non-small cell lung cancer progression[J]. Virulence, 2025, 16(1): 2548626.

[19] Li C, Zhao H, Wang J, et al. A tumor-resident bacterium promotes cervical cancer progression through lysoPC-mediated c-Jun/c-Fos activation[J]. Cell Rep, 2026, 45(3): 117079.

[20] He Z, Yu J, Gong J, et al. Campylobacter jejuni-derived cytolethal distending toxin promotes colorectal cancer metastasis[J]. Cell Host Microbe, 2024, 32(12): 2080-2091.e6.

[21] Yu J, Lu W, Chen Y, et al. Butyrate derived from intratumoral microbiome facilitates pulmonary metastasis in osteosarcoma[J]. Pharmacol Res, 2025, 219: 107897.

[22] Yan L, Wei X, Zhong F, et al. Intratumoral microbial community profiling identifies clinicomolecular and prognostic subtypes of colorectal cancer liver metastasis[J]. npj Precis Oncol, 2025, 9: 284.

[23] Yang Y, Yang R, Chen Y, et al. Acinetobacter baumannii promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation[J]. Gut, 2026: gutjnl-2025-336161.

[24] Yang L, Li A, Wang Y, et al. Intratumoral microbiota: Roles in cancer initiation, development and therapeutic efficacy[J]. Signal Transduct Target Ther, 2023, 8: 35.

[25] Xu W, Zhang Y, Chen D, et al. Elucidating the genotoxicity of Fusobacterium nucleatum-secreted mutagens in colorectal cancer carcinogenesis[J]. Gut Pathog, 2024, 16(1): 50.

[26] Dougherty M W, Valdés-Mas R, Wernke K M, et al. The microbial genotoxin colibactin exacerbates mismatch repair mutations in colorectal tumors[J]. Neoplasia, 2023, 43: 100918.

[27] Zhang R, Li M, Tan H, et al. A new gut pathogenic bacteria and its metabolites promote colorectal cancer development and act as non-invasive early diagnostic biomarkers[J]. Gut Microbes, 2025, 17: 2555446.

[28] Poetsch A R. The genomics of oxidative DNA damage, repair, and resulting mutagenesis[J]. Comput Struct Biotechnol J, 2020, 18: 207-219.

[29] Srinivas U S, Tan B W Q, Vellayappan B A, et al. ROS and the DNA damage response in cancer[J]. Redox Biol, 2019, 25: 101084.

[30] Miyakawa Y, Otsuka M, Shibata C, et al. Gut bacteria-derived membrane vesicles induce colonic dysplasia by inducing DNA damage in colon epithelial cells[J]. Cell Mol Gastroenterol Hepatol, 2024, 17(5): 745-767.

[31] Nandi D, Parida S, Verma D, et al. Spermine oxidase serves as a key functional node in microbial dysbiosis-induced breast carcinogenesis[J]. Cancer Res, 2026, 86(8): 1920-1938.

[32] Tajpara P, Sobkowiak M J, Healy K, et al. Patient-derived pancreatic tumor bacteria exhibit oncogenic properties and are recognized by MAIT cells in tumor spheroids[J]. Front Immunol, 2025, 16: 1553034.

[33] Liao Q, Zhou X, Wu L, et al. Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs[J]. J Clin Investig, 2025, 135(11): e181243.

[34] Ternes D, Tsenkova M, Pozdeev V I, et al. The gut microbial metabolite formate exacerbates colorectal cancer progression[J]. Nat Metab, 2022, 4(4): 458-475.

[35] Yuan L, Pan L, Wang Y, et al. Characterization of the landscape of the intratumoral microbiota reveals that Streptococcus anginosus increases the risk of gastric cancer initiation and progression[J]. Cell Discov, 2024, 10(1): 117.

[36] Cheng G, Jiang X, Zhu L, et al. Intratumoral Parvimonas micra promotes esophageal squamous cell carcinoma via p-cresol-induced T_reg differentiation [J]. Sci Adv, 2026, 12(8): eady1644.

[37] Ma Y, Chen H, Li H, et al. Intratumor microbiome-derived butyrate promotes lung cancer metastasis[J]. Cell Rep Med, 2024, 5(4): 101488.

[38] Li X, Wang Y, Wu Y, et al. Intratumor microbiome-derived butyrate enhances progesterone sensitivity by inducing ferroptosis in endometrial cancer[J]. Pharmacol Res, 2025, 219: 107902.

[39] Kalaora S, Nagler A, Nejman D, et al. Identification of bacteria-derived HLA-bound peptides in melanoma[J]. Nature, 2021, 592(7852): 138-143.

[40] Chai X, Wang J, Li H, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma[J]. Gut Microbes, 2023, 15: 2156255.

[41] Yang R, Yang Y, Lin W, et al. Lactobacillus paracasei ZJUZ2-3 inhibits gastrointestinal tumors via the IAA-induced AHR/MTDH/NF-κB axis[J]. Int J Biol Sci, 2025, 21(14): 6522-6541.

[42] Sun Y, Wang Q, Jiang Y, et al. Lactobacillus intestinalis facilitates tumor-derived CCL5 to recruit dendritic cell and suppress colorectal tumorigenesis[J]. Gut Microbes, 2025, 17: 2449111.

[43] Lam K C, Araya R E, Huang A, et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment[J]. Cell, 2021, 184(21): 5338-5356.e21.

[44] Silva de Oliveira R, Shupe A, Krause T, et al. Bifidobacteria-derived exopolysaccharide promotes anti-tumor immunity[J]. Cell Rep, 2025, 44(9): 116223.

[45] Zhong Y, Zhang D, Ding F, et al. Intratumoral microbiota-driven macrophage reprogramming in pancreatic cancer via Blautia metabolite 6-hydroxyhexanoic acid[J]. Int Immunopharmacol, 2025, 164: 115421.

[46] Pan B, Zhang X, Ye D, et al. Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma[J]. Cell Death Dis, 2025, 16: 407.

[47] Mimpen I L, Battaglia T W, Parra-Martinez M, et al. Microbial metabolic pathways guide response to immune checkpoint blockade therapy[J]. Cancer Discov, 2026, 16(1): 95-113.

[48] Fong W, Li Q, Lau H C, et al. 461 Lactobacillus gallinarum-derived metabolites boost anti-Pd1 efficacy in colorectal cancer by inhibiting regulatory t cells through ido1/kyn/ahr axis[J]. Gastroenterology, 2023, 164(6): S-88.

[49] Bender M J, McPherson A C, Phelps C M, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment[J]. Cell, 2023, 186(9): 1846-1862.e26.

[50] Wang X, Fang Y, Liang W, et al. Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer[J]. Cancer Cell, 2024, 42(10): 1729-1746.e8.

[51] Chen X, Zhang Y, Zhang G, et al. Spatial microbiome-metabolic crosstalk drives CD8⁺ T-cell exhaustion through the butyrate-HDAC axis in colorectal cancer [J]. Front Microbiol, 2025, 16: 1704491.

[52] Song Q, Li X, Li Q, et al. Bifidobacterium animalis suppresses non-small cell lung cancer progression and modulates tumor immunity through indole-3-acetic acid[J]. Cell Rep, 2025, 44(8): 116132.

[53] Brennan C A, Garrett W S. Fusobacterium nucleatum-symbiont, opportunist and oncobacterium[J]. Nat Rev Microbiol, 2019, 17(3): 156-166.

[54] Xue Y, Xiao H, Guo S, et al. Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages[J]. Cell Death Dis, 2018, 9: 355.

[55] Donohoe D R, Holley D, Collins L B, et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner[J]. Cancer Discov, 2014, 4(12): 1387-1397.

[56] Bultman S J. The microbiome and its potential as a cancer preventive intervention[J]. Semin Oncol, 2016, 43(1): 97-106.

[57] Lazarova D L, Chiaro C, Bordonaro M. Butyrate induced changes in Wnt-signaling specific gene expression in colorectal cancer cells[J]. BMC Res Notes, 2014, 7(1): 226.

[58] He Y, Fu L, Li Y, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8⁺ T cell immunity [J]. Cell Metab, 2021, 33(5): 988-1000.e7.

[59] Ma S, Li X, Shang S, et al. Targeting gut microbiota and metabolites in cancer radiotherapy[J]. Clin Transl Med, 2025, 15(10): e70481.

[60] Shang S, Liu J, Verma V, et al. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates[J]. Cancer Commun, 2021, 41(11): 1086-1099.

[61] LaCourse K D, Zepeda-Rivera M, Kempchinsky A G, et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota[J]. Cell Rep, 2022, 41(7): 111625.

[62] Ahmad Khan Z, Sobkowiak M J, Ghorbani M, et al. Survival mechanism of pancreatic tumor bacteria and their ability to metabolize chemotherapy drugs[J]. Microbiol Spectr, 2025, 13(9): e01820-e01825.

[63] Colbert L E, El Alam M B, Wang R, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring[J]. Cancer Cell, 2023, 41(11): 1945-1962.e11.

[64] Jiang S S, Xie Y L, Xiao X Y, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer[J]. Cell Host Microbe, 2023, 31(5): 781-797.e9.

[65] Wang J, Nan Y, Liu Q, et al. Tumor-Resident Streptococcus pneumoniae Promotes malignant progression and pazopanib resistance in clear cell renal cell carcinoma[J]. Cancer Res, 2026, 86(9): 2237-2252.

[66] Xu Q, Gao J, Zhao R, et al. Akkermansia muciniphila-derived pentadecanoic acid enhances oxaliplatin sensitivity in gastric cancer by modulating glycolysis[J]. Pharmacol Res, 2024, 206: 107278.

[67] Zhang L, Jiang L, Yu L, et al. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses[J]. Nat Commun, 2022, 13: 5413.

[68] Mager L F, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510): 1481-1489.

[69] Chandra D, Chellakkan Selvanesan B, Yuan Z, et al. 32-Phosphorus selectively delivered by Listeria to pancreatic cancer demonstrates a strong therapeutic effect[J]. Oncotarget, 2017, 8(13): 20729-20740.

[70] Jahangir A, Chandra D, Quispe-Tintaya W, et al. Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms[J]. OncoImmunology, 2017, 6(9): e1342025.

[71] Canale F P, Basso C, Antonini G, et al. Metabolic modulation of tumours with engineered bacteria for immunotherapy[J]. Nature, 2021, 598(7882): 662-666.

[72] Huang Y, Zhu N, Zheng X, et al. Intratumor microbiome analysis identifies positive association between Megasphaera and survival of Chinese patients with pancreatic ductal adenocarcinomas[J]. Front Immunol, 2022, 13: 785422.

[73] Li X, Wang Y, Xie H, et al. Engineering Escherichia coli Nissle 1917 to scavenge lactate enhances anti-tumor immunity[J]. J Control Release, 2026, 392: 114738.

[74] Wang L, Wu Q, Lyu Q, et al. Genetically designed living bacteria with melanogenesis for tumor-specific pigmentation and therapeutic intervention[J]. Adv Sci, 2024, 11(31): 2402709.

[75] 陈春屹, 余曦晨, 王迪, 等. 3种中药纳米乳剂对耳念珠菌深部感染小鼠的抗菌效果[J]. 贵州医科大学学报, 2024, 49(9): 1269-1275.

[76] Wu B, Yao C, Wang H, et al. Ellagic acid-protein nanocomplex inhibits tumor growth by reducing the intratumor bacteria and inhibiting histamine production[J]. Biomaterials, 2025, 317: 123078.

[77] Kong F, Fang C, Zhang Y, et al. Abundance and metabolism disruptions of intratumoral microbiota by chemical and physical actions unfreeze tumor treatment resistance[J]. Adv Sci, 2022, 9(7): 2105523.

[78] Li S, Gao Y, Jiang D, et al. Ultrasound-activated nanoplatform counteracts triple-negative breast cancer via remodeling intratumoral microbiota-metabolism and inducing ferroptosis[J]. Biomater Res, 2026, 30: 317.

[79] McQuade J L, Daniel C R, Helmink B A, et al. Modulating the microbiome to improve therapeutic response in cancer[J]. Lancet Oncol, 2019, 20(2): e77-e91.

[80] Sorbara M T, Pamer E G. Microbiome-based therapeutics[J]. Nat Rev Microbiol, 2022, 20(6): 365-380.

[81] Esaiassen E, Hjerde E, Cavanagh J P, et al. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity[J]. J Clin Microbiol, 2017, 55(7): 2234-2248.

基金资助

国家自然科学基金(82260486)

云南省重大科技专项基金(202302AA310039-02)